Publications by authors named "J-P Machiels"
Purpose: This multicenter phase Ib study investigated trastuzumab deruxtecan (T-DXd) plus nivolumab in patients with HER2-expressing metastatic breast cancer (mBC) and metastatic urothelial cancer (mUC).
Patients And Methods: Part 1 determined the recommended dose for expansion of T-DXd plus nivolumab. Part 2 evaluated efficacy and safety; the primary endpoint was confirmed objective response rate by independent central review.
Article Synopsis
- A first-in-human study was conducted to evaluate the safety and efficacy of acapatamab, a bispecific T-cell engager targeting metastatic castration-resistant prostate cancer (mCRPC).
- 133 patients participated, receiving varying doses of acapatamab; the most common side effect was cytokine release syndrome (CRS), noted in a large majority, particularly during the first treatment cycle.
- Preliminary results showed some antitumor activity, with 30.4% of patients experiencing confirmed PSA responses, though the overall durable activity was limited and further evaluation is needed.
Article Synopsis
- The study aimed to create and validate a radiomic model using [F]FDG PET scans to predict overall survival in patients with head and neck squamous cell carcinoma (HNSCC).
- It involved analyzing two datasets of patients treated with afatinib, extracting radiomic features from their PET scans, and using these features alongside clinical data to develop a Cox regression model for predictions.
- The radiomic model showed better performance in predicting survival than clinical models alone, suggesting that combining radiomic features with clinical variables could enhance predictions, though further validation with larger patient groups is needed.
In 2019, the FDA approved pembrolizumab, a monoclonal antibody targeting PD-1, for the first-line treatment of recurrent or metastatic head and neck cancers, despite only a limited number of patients benefiting from the treatment. Promising effects of therapeutic vaccination led the FDA to approve the use of the first therapeutic vaccine in prostate cancer in 2010. Research in the field of therapeutic vaccination, including possible synergistic effects with anti-PD(L)1 treatments, is evolving each year, and many vaccines are in pre-clinical and clinical studies.
View Article and Find Full Text PDFArticle Synopsis
- Monalizumab is a type of medicine that helps boost our immune cells to fight certain cancers, especially in the head and neck.
- In a study called UPSTREAM, doctors tested how well monalizumab worked for patients with a specific kind of cancer after other treatments didn't work.
- The results showed that while some patients had stable cancer for a short time, the medicine didn't really help most of them, so doctors are now looking at combining it with another treatment for better results.